| Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis B Ley, J Swigris, B Day, JL Stauffer, K Raimundo, W Chou, HR Collard American journal of respiratory and critical care medicine 196 (6), 756-761, 2017 | 211 | 2017 |
| Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria A Kaplan, M Ferrer, JA Bernstein, E Antonova, B Trzaskoma, K Raimundo, ... Journal of Allergy and Clinical Immunology 137 (2), 474-481, 2016 | 197 | 2016 |
| Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis ER Fernández Pérez, AM Kong, K Raimundo, TL Koelsch, R Kulkarni, ... Annals of the American Thoracic Society 15 (4), 460-469, 2018 | 183 | 2018 |
| Rheumatoid arthritis–interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality K Raimundo, JJ Solomon, AL Olson, AM Kong, AL Cole, A Fischer, ... The Journal of rheumatology 46 (4), 360-369, 2019 | 166 | 2019 |
| Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study K Raimundo, E Chang, MS Broder, K Alexander, J Zazzali, JJ Swigris BMC Pulmonary Medicine 16, 1-8, 2016 | 88 | 2016 |
| Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use JL Zazzali, MS Broder, TA Omachi, E Chang, GH Sun, K Raimundo Allergy Asthma Proc 36 (4), 268-274, 2015 | 86 | 2015 |
| Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria MS Broder, K Raimundo, E Antonova, E Chang American journal of clinical dermatology 16, 313-321, 2015 | 68 | 2015 |
| Clinical and economic burden of antineutrophil cytoplasmic antibody–associated vasculitis in the United States K Raimundo, AM Farr, G Kim, G Duna The Journal of rheumatology 42 (12), 2383-2391, 2015 | 46 | 2015 |
| Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the … CH Holtze, EA Freiheit, SL Limb, JL Stauffer, K Raimundo, WT Pan, ... Respiratory research 21, 1-10, 2020 | 37 | 2020 |
| Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. JL Zazzali, KP Raimundo, B Trzaskoma, KE Rosén, M Schatz Allergy & Asthma Proceedings 36 (4), 2015 | 37 | 2015 |
| All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement A Fischer, AM Kong, JJ Swigris, AL Cole, K Raimundo The Journal of rheumatology 45 (2), 235-241, 2018 | 36 | 2018 |
| Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity K Raimundo, H Tian, H Zhou, X Zhang, KH Kahler, N Agashivala, E Kim BMC health services research 13, 1-8, 2013 | 35 | 2013 |
| Validation of an ICD-9–based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria D Cherepanov, K Raimundo, E Chang, M Eagan, JL Zazzali, PG Solari, ... Annals of Allergy, Asthma & Immunology 114 (5), 393-398, 2015 | 34 | 2015 |
| Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden JJ Mooney, K Raimundo, E Chang, MS Broder BMC pulmonary medicine 17, 1-9, 2017 | 33 | 2017 |
| Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies JL Zazzali, A Kaplan, M Maurer, K Raimundo, B Trzaskoma, PG Solari, ... Annals of Allergy, Asthma & Immunology 117 (4), 370-377. e1, 2016 | 32 | 2016 |
| Hospital cost and length of stay in idiopathic pulmonary fibrosis JJ Mooney, K Raimundo, E Chang, MS Broder Journal of Medical Economics 20 (5), 518-524, 2017 | 31 | 2017 |
| Development and initial validation analyses of the living with idiopathic pulmonary fibrosis questionnaire JJ Swigris, DA Andrae, T Churney, N Johnson, MB Scholand, ES White, ... American Journal of Respiratory and Critical Care Medicine 202 (12), 1689-1697, 2020 | 30 | 2020 |
| Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients GS Sawicki, W Chou, K Raimundo, B Trzaskoma, MW Konstan Journal of Cystic Fibrosis 14 (6), 777-783, 2015 | 30 | 2015 |
| Treatment selection and experience in multiple sclerosis: survey of neurologists KA Hanson, N Agashivala, KW Wyrwich, K Raimundo, E Kim, ... Patient preference and adherence, 415-422, 2014 | 26 | 2014 |
| Potential delays in diagnosis of idiopathic pulmonary fibrosis in Medicare beneficiaries J Mooney, E Chang, D Lalla, E Papoyan, K Raimundo, SR Reddy, ... Annals of the American Thoracic Society 16 (3), 393-396, 2019 | 24 | 2019 |
